Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655911 · ClinicalTrials.gov registry record
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
A clinical trial, sponsored by Abeona Therapeutics.
- Terminated
- Registry status
- 1
- Enrollment target
NCT04655911: Clinical Trial study, sponsored by Abeona Therapeutics.
NCT04655911 is a clinical trial that was terminated before completion, run by Abeona Therapeutics. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04655911 was terminated before completion, sponsored by Abeona Therapeutics.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 years post-treatment).
Primary Outcome
Long-term product safety as defined by the incidence, type, and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Interventions
- BIOLOGICAL ABO-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2022-04-07 |
Why NCT04655911 stopped before completion
NCT04655911 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ABO-101 is the first listed.
NCT04655911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04655911 about?
NCT04655911 is a clinical study titled "A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101". This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 year...
What is the current status of trial NCT04655911?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2020-10-28. Estimated completion is 2022-04-07.
What interventions are being tested in trial NCT04655911?
The interventions under investigation include: ABO-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04655911?
This trial is sponsored by Abeona Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI